AAPL 250.9362 1.1636% MSFT 439.85 0.5624% NVDA 132.26 2.5987% GOOGL 190.36 1.0403% GOOG 191.585 0.7547% AMZN 224.7026 1.8967% META 605.1 1.3245% AVGO 221.57 -0.9167% TSLA 434.8 -1.211% TSM 195.3 -0.133% LLY 758.87 -0.7637% V 315.9 1.9756% JPM 234.325 1.7168% UNH 493.79 -1.1867% NVO 103.7 -2.1329% WMT 93.89 0.3634% LVMUY 130.52 0.7721% XOM 105.67 -0.7048% LVMHF 649.5 0.6649% MA 526.755 1.3068%
Last update at 2024-11-27T14:30:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -119.68700M | -75.08200M | -105.31400M | -94.43300M | -64.77500M |
| Minority interest | - | - | - | - | - |
| Net income | -113.12700M | -74.95500M | -104.61100M | -90.92600M | -64.77500M |
| Selling general administrative | 28.97M | 25.93M | 21.41M | 19.41M | 11.81M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 9.27M | 46.72M | 4.04M | 4.37M | 1.19M |
| Reconciled depreciation | 6.56M | 6.35M | 6.64M | 4.75M | 3.96M |
| Ebit | -120.42800M | -75.20900M | -106.01700M | -97.94000M | -65.58400M |
| Ebitda | -118.45200M | -68.86200M | -99.37300M | -93.19500M | -61.62300M |
| Depreciation and amortization | 1.98M | 6.35M | 6.64M | 4.75M | 3.96M |
| Non operating income net other | -0.00700M | -0.07300M | - | - | - |
| Operating income | -120.42800M | -75.20900M | -106.01700M | -97.94000M | -65.58400M |
| Other operating expenses | 129.70M | 121.93M | 110.05M | 102.31M | 66.77M |
| Interest expense | 1.24M | 0.13M | 0.70M | 0.00000M | 0.00000M |
| Tax provision | - | - | - | - | - |
| Interest income | 1.98M | 0.13M | 0.70M | 3.51M | 0.81M |
| Net interest income | 0.74M | 0.13M | 0.70M | 3.51M | 0.81M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -6.56000M | -0.12700M | -0.70300M | -3.50700M | 0.81M |
| Total revenue | 9.27M | 46.72M | 4.04M | 4.37M | 1.19M |
| Total operating expenses | 129.70M | 121.93M | 110.05M | 102.31M | 66.77M |
| Cost of revenue | - | - | - | 82.90M | 54.97M |
| Total other income expense net | 0.74M | 0.13M | 0.70M | 3.51M | 0.81M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -119.69400M | -75.15500M | -105.31400M | -94.43300M | -64.77500M |
| Net income applicable to common shares | -119.68700M | -75.08200M | -105.31400M | -94.43300M | -64.77500M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 177.77M | 240.75M | 278.11M | 221.57M | 184.39M |
| Intangible assets | - | - | - | 0.52M | 0.58M |
| Earning assets | - | - | - | - | - |
| Other current assets | 5.63M | 7.01M | 0.87M | 0.27M | 0.29M |
| Total liab | 125.92M | 69.97M | 62.02M | 54.83M | 50.05M |
| Total stockholder equity | 51.85M | 170.78M | 216.09M | 166.74M | 134.34M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 14.27M | 15.68M | 11.04M | 8.06M | 7.42M |
| Common stock | 0.02M | 0.02M | 0.02M | 0.02M | 0.02M |
| Capital stock | 0.02M | 0.02M | 0.02M | 0.02M | 0.02M |
| Retained earnings | -659.56100M | -521.07100M | -401.38400M | -326.30200M | -220.98800M |
| Other liab | - | 0.15M | 3.13M | 8.62M | 9.56M |
| Good will | - | - | - | - | - |
| Other assets | - | 15.03M | 8.36M | 23.07M | 2.78M |
| Cash | 65.28M | 55.50M | 93.29M | 170.06M | 57.41M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 27.34M | 34.80M | 39.96M | 26.99M | 19.50M |
| Current deferred revenue | 2.35M | 5.13M | 17.20M | 3.48M | 4.96M |
| Net debt | 39.49M | -15.18200M | -66.86800M | -144.95700M | -33.91800M |
| Short term debt | 6.90M | 5.29M | 7.48M | 5.87M | 2.50M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 104.78M | 40.32M | 26.42M | 25.10M | 23.49M |
| Other stockholder equity | 711.39M | 691.91M | 617.52M | 493.02M | 355.29M |
| Property plant equipment | - | 21.34M | 44.54M | 22.11M | 50.34M |
| Total current assets | 87.44M | 182.88M | 220.59M | 175.39M | 131.27M |
| Long term investments | 0.00000M | 4.03M | 4.62M | - | - |
| Net tangible assets | - | 170.78M | 216.09M | 166.74M | 134.34M |
| Short term investments | 16.29M | 116.39M | 108.35M | 1.00M | 70.37M |
| Net receivables | 0.23M | 0.66M | 2.37M | - | 0.48M |
| Long term debt | 40.14M | 19.35M | - | - | - |
| Inventory | - | 3.31M | 15.73M | - | 2.73M |
| Accounts payable | 3.82M | 8.69M | 4.23M | 9.58M | 4.62M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 0.00300M | -0.08000M | -0.07300M | - | 0.02M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 0.02M | 0.02M | 0.02M | 0.02M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | -521.07100M | -401.38400M | -326.30200M | -220.98800M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.92M | 15.03M | 8.36M | 2.21M | 2.19M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 90.33M | 57.88M | 57.52M | 46.18M | 53.12M |
| Capital lease obligations | 64.63M | 20.97M | 26.42M | 25.10M | 23.49M |
| Long term debt total | - | 19.35M | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -7.09200M | -112.85200M | 69.46M | 32.01M | -53.44000M |
| Change to liabilities | 6.68M | 8.21M | 2.56M | 0.69M | 4.97M |
| Total cashflows from investing activities | -12.96400M | -118.55300M | 65.95M | 15.84M | -59.10300M |
| Net borrowings | 18.71M | -0.05600M | -0.10400M | -0.80700M | -0.05600M |
| Total cash from financing activities | 83.10M | 108.76M | 135.80M | 74.39M | 110.44M |
| Change to operating activities | -11.20800M | -9.57800M | -2.93600M | -1.40300M | -1.85300M |
| Net income | -119.68700M | -75.08200M | -105.31400M | -94.43300M | -64.77500M |
| Change in cash | -45.81200M | -60.47100M | 112.65M | 5.22M | 13.18M |
| Begin period cash flow | 110.58M | 171.05M | 58.40M | 53.17M | 40.00M |
| End period cash flow | 64.77M | 110.58M | 171.05M | 58.40M | 53.17M |
| Total cash from operating activities | -115.94600M | -50.67800M | -89.10200M | -85.01100M | -38.16200M |
| Issuance of capital stock | 64.74M | 112.89M | 135.91M | 75.20M | 113.52M |
| Depreciation | 6.56M | 6.35M | 6.64M | 4.75M | 3.96M |
| Other cashflows from investing activities | - | -0.23800M | -0.23800M | 32.01M | -53.44000M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | - | - | - | - |
| Change to account receivables | - | - | - | - | - |
| Sale purchase of stock | 65.51M | 117.21M | 10.88M | 75.20M | 113.52M |
| Other cashflows from financing activities | 18.59M | -4.07200M | -0.10400M | -0.80700M | 17.86M |
| Change to netincome | 3.64M | 19.42M | 3.31M | 5.35M | 3.00M |
| Capital expenditures | 5.87M | 5.46M | 3.52M | 16.17M | 5.66M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | -13.15900M | 14.44M | 3.82M | -0.02200M | 15.24M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | -45.81200M | -60.47100M | 112.65M | 5.22M | 13.18M |
| Change in working capital | -24.52700M | -1.36400M | -4.93100M | -5.65500M | 20.21M |
| Stock based compensation | 12.56M | 10.55M | 7.11M | 5.30M | 3.00M |
| Other non cash items | 9.15M | 8.05M | 7.51M | 6.38M | -0.55200M |
| Free cash flow | -121.81800M | -56.14100M | -92.61700M | -101.18400M | -43.82500M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| GRTS Gritstone Oncology Inc |
0.01 66.84% | 0.03 | - | - | 5.48 | 1.73 | 86.36 | -0.906 |
| NVO Novo Nordisk A/S |
-2.26 2.13% | 103.70 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-1.68 1.57% | 105.12 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-55.6951 12.45% | 391.80 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
-4.445 0.62% | 710.17 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
5959 Horton Street, EmeryVille, CA, United States, 94608
| Name | Title | Year Born |
|---|---|---|
| Dr. Andrew R. Allen BCh, BM, M.D., MA, MRCP, Ph.D. | Co-Founder, Pres, CEO & Director | 1967 |
| Mr. Erin E. Jones M.S. | Exec. VP & COO | 1972 |
| Dr. Karin Jooss Ph.D. | Exec. VP and Head of R&D | 1965 |
| Ms. Vassiliki Economides | Exec. VP & CFO | 1981 |
| Mr. James Cho | Chief Accounting Officer | NA |
| Ms. Stacy Proctor | Sr. VP & Head of People | NA |
| Dr. Matthew J. Hawryluk M.B.A., Ph.D. | Exec. VP & Chief Bus. Officer | 1978 |
| Mr. Vijay Yabannavar Ph.D. | Exec. VP & Chief Technical Devel. Officer | 1962 |
| Dr. Andrew R. Allen BCh, BM, M.D., MA, MRCP, Ph.D. | Co-Founder, President, CEO & Director | 1966 |
| Mr. Erin E. Jones M.S. | Executive VP & COO | 1972 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...